Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made
In ATTAIN-MAINTAIN, patients who had plateaued after injectable therapy switched to oral orforglipron, marketed as Foundayo
They represent the lived experiences of patients who have been told their labs are normal, that they just need to try harder, or who have cycled through diet after diet without understanding why their body seems to be working against them at every turn
Providers evaluate contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastroparesis
How long does it take semaglutide to suppress appetite